Sagimet Biosciences
PublicSagimet Biosciences is now publicly traded
The data on this page reflects Sagimet Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 13, 2023
Last Round
Follow-on Offering
Jan 25, 2024
Total Funding Raised
$399.4M
Company Overview
Sagimet Biosciences (NAS: SGMT) is a biopharmaceutical company dedicated to developing selective fatty acid synthase (FASN) inhibitors for treating diseases linked to dysfunctional lipid metabolism, with its lead candidate, denifanstat, being an oral medication aimed at nonalcoholic steatohepatitis (NASH).
Sector
Healthcare
AI Layer
Non-AI
Keywords
Sagimet Biosciences Comparables
Compare Sagimet Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Galea Therapeutics | 75% | |
| NorthSea Therapeutics | 72% | |
| OrsoBio | 70% | |
Sagimet Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jan 25, 2024 | ||||
| IPO | Jul 13, 2023 | ||||
| Growth Equity | Feb 11, 2021 | ||||
| Series E | Aug 5, 2019 | ||||
| Series D | Dec 30, 2014 | ||||
Series C | Jun 21, 2013 |
Sagimet Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series C, Series A |
| New Enterprise Associates (NEA) | Series E, Growth Equity, Series B, Series C, Series D |
| Ally Bridge Group | Series D |
| Altium Capital | Growth Equity |
| The Chernin Group | Series B, Series A |
| TD Cowen | Follow-on Offering |
| HM Capital | Growth Equity |
Sagimet Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
